Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C23H24N6O5S2.H2O4S |
Molecular Weight | 626.682 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(O)(=O)=O.[H][C@]12SCC(C[N+]3=C4CCCCC4=CC=C3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C5=CSC(N)=N5)C([O-])=O
InChI
InChIKey=KYOHRXSGUROPGY-OFNLCGNNSA-N
InChI=1S/C23H24N6O5S2.H2O4S/c1-34-27-16(14-11-36-23(24)25-14)19(30)26-17-20(31)29-18(22(32)33)13(10-35-21(17)29)9-28-8-4-6-12-5-2-3-7-15(12)28;1-5(2,3)4/h4,6,8,11,17,21H,2-3,5,7,9-10H2,1H3,(H3-,24,25,26,30,32,33);(H2,1,2,3,4)/b27-16-;/t17-,21-;/m1./s1
Molecular Formula | HO4S |
Molecular Weight | 97.071 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C23H25N6O5S2 |
Molecular Weight | 529.612 |
Charge | 1 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 1 |
Optical Activity | UNSPECIFIED |
Cefquinome is a 4th generation cephalosporin which is active against a broad spectrum of Gram positive and Gram negative bacteria. As many cephalosporin it acts by binding to bacterial PBP and thus inhibiting the cell wall synthesis. Cefquinome is approved for veterinary use in cattles with respiratory tract infections, skin infections, bacterial mastitis and septicaemia.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2354204 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | COBACTAN Approved UseTreatment of infections caused by bacteria sensitive to cefquinome, such as: (1) Respiratory tract infections caused by Pasteurella multocida and Mannheimia haemolytica. (2) Digital dermatitis, infectious bulbar necrosis and interdigital necrobacillosis (foul in foot). (3) Acute E.coli mastitis with signs of systemic involvement. (4) Calf-E.coli septicaemia. Launch Date2006 |
|||
Curative | COBACTAN Approved UseTreatment of infections caused by bacteria sensitive to cefquinome, such as: (1) Respiratory tract infections caused by Pasteurella multocida and Mannheimia haemolytica. (2) Digital dermatitis, infectious bulbar necrosis and interdigital necrobacillosis (foul in foot). (3) Acute E.coli mastitis with signs of systemic involvement. (4) Calf-E.coli septicaemia. Launch Date2006 |
|||
Curative | COBACTAN Approved UseTreatment of infections caused by bacteria sensitive to cefquinome, such as: (1) Respiratory tract infections caused by Pasteurella multocida and Mannheimia haemolytica. (2) Digital dermatitis, infectious bulbar necrosis and interdigital necrobacillosis (foul in foot). (3) Acute E.coli mastitis with signs of systemic involvement. (4) Calf-E.coli septicaemia. Launch Date2006 |
|||
Curative | COBACTAN Approved UseTreatment of infections caused by bacteria sensitive to cefquinome, such as: (1) Respiratory tract infections caused by Pasteurella multocida and Mannheimia haemolytica. (2) Digital dermatitis, infectious bulbar necrosis and interdigital necrobacillosis (foul in foot). (3) Acute E.coli mastitis with signs of systemic involvement. (4) Calf-E.coli septicaemia. Launch Date2006 |
|||
Curative | COBACTAN Approved UseTreatment of infections caused by bacteria sensitive to cefquinome, such as: (1) Respiratory tract infections caused by Pasteurella multocida and Mannheimia haemolytica. (2) Digital dermatitis, infectious bulbar necrosis and interdigital necrobacillosis (foul in foot). (3) Acute E.coli mastitis with signs of systemic involvement. (4) Calf-E.coli septicaemia. Launch Date2006 |
|||
Curative | COBACTAN Approved UseTreatment of infections caused by bacteria sensitive to cefquinome, such as: (1) Respiratory tract infections caused by Pasteurella multocida and Mannheimia haemolytica. (2) Digital dermatitis, infectious bulbar necrosis and interdigital necrobacillosis (foul in foot). (3) Acute E.coli mastitis with signs of systemic involvement. (4) Calf-E.coli septicaemia. Launch Date2006 |
PubMed
Title | Date | PubMed |
---|---|---|
Antibacterial activities in vitro and in vivo and pharmacokinetics of cefquinome (HR 111V), a new broad-spectrum cephalosporin. | 1991 Jan |
|
In vitro activities of cephalosporins and quinolones against Escherichia coli strains isolated from diarrheic dairy calves. | 1999 Mar |
|
Selection and persistence of CTX-M-producing Escherichia coli in the intestinal flora of pigs treated with amoxicillin, ceftiofur, or cefquinome. | 2008 Oct |
|
Factors affecting cure when treating bovine clinical mastitis with cephalosporin-based intramammary preparations. | 2009 May |
|
Development and validation of a high-performance liquid chromatography method for determination of cefquinome concentrations in sheep plasma and its application to pharmacokinetic studies. | 2011 Feb |
|
Development of stability-indicating methods for cefquinome sulphate. | 2013 Sep |
|
Comparative Pharmacokinetics of Cefquinome (Cobactan 2.5%) following Repeated Intramuscular Administrations in Sheep and Goats. | 2014 |
|
Stability-indicating HPLC method for the determination of cefquinome sulfate. | 2014 Mar-Apr |
Patents
Sample Use Guides
1 mg cefquinome/kg (2ml/50 kg body wt.) or 2 mg cefquinome/kg (4ml/50 kg body wt.) given by intramuscular injection (2,5% Cobactan solution).
Route of Administration:
Intramuscular
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2014969
The MICs of cefquinome against single laboratory strains of gram-positive and gram-negative anaerobic bacteria were determined. The values were (MIC50): 0.781 ug/ml for Staphylococcus aureus (Methicillin susceptible); 12.5 ug/ml for Staphylococcus aureus (Methicillin resistant); <0.006 ug/ml for Streptococcus spp.; 4.0 ug/ml for Enterococci; 0.049 ug/ml for E.Coli and Klebsiella spp.; 0.098 ug/ml for Salmonella spp., Enterobacter spp. and Proteus mirabilis; 0.195 ug/ml for Serratia marcescens and Proteus spp.; 0.002 ug/ml for Streptococcus pyogenes; 0.008 ug/ml for Streptococcus pneumoniae and Klebsiella pneumoniae; 0.078 ug/ml for Pasteurella multocida, Proteus mirabilis ATCC 14273; 0.03 ug/ml for Escherichia coli 078 and 0.06 ug/ml for Salmonella typhimurium MZ II.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:52:44 GMT 2023
by
admin
on
Fri Dec 15 15:52:44 GMT 2023
|
Record UNII |
3858K104DQ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C357
Created by
admin on Fri Dec 15 15:52:44 GMT 2023 , Edited by admin on Fri Dec 15 15:52:44 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
9577261
Created by
admin on Fri Dec 15 15:52:44 GMT 2023 , Edited by admin on Fri Dec 15 15:52:44 GMT 2023
|
PRIMARY | |||
|
CHEMBL1631107
Created by
admin on Fri Dec 15 15:52:44 GMT 2023 , Edited by admin on Fri Dec 15 15:52:44 GMT 2023
|
PRIMARY | |||
|
118443-89-3
Created by
admin on Fri Dec 15 15:52:44 GMT 2023 , Edited by admin on Fri Dec 15 15:52:44 GMT 2023
|
PRIMARY | |||
|
DTXSID6048593
Created by
admin on Fri Dec 15 15:52:44 GMT 2023 , Edited by admin on Fri Dec 15 15:52:44 GMT 2023
|
PRIMARY | |||
|
300000023790
Created by
admin on Fri Dec 15 15:52:44 GMT 2023 , Edited by admin on Fri Dec 15 15:52:44 GMT 2023
|
PRIMARY | |||
|
m3214
Created by
admin on Fri Dec 15 15:52:44 GMT 2023 , Edited by admin on Fri Dec 15 15:52:44 GMT 2023
|
PRIMARY | Merck Index | ||
|
3858K104DQ
Created by
admin on Fri Dec 15 15:52:44 GMT 2023 , Edited by admin on Fri Dec 15 15:52:44 GMT 2023
|
PRIMARY | |||
|
C81032
Created by
admin on Fri Dec 15 15:52:44 GMT 2023 , Edited by admin on Fri Dec 15 15:52:44 GMT 2023
|
PRIMARY | |||
|
HH-33
Created by
admin on Fri Dec 15 15:52:44 GMT 2023 , Edited by admin on Fri Dec 15 15:52:44 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |